2026 ACC Expert Consensus Decision Pathway Overhauls HFpEF Management

This updated ACC expert consensus pathway establishes SGLT2 inhibitors and nonsteroidal MRAs as foundational HFpEF therapy and formally integrates incretin-based agents for obesity-related disease.

📅 Journal publication: Jul 23, 2026 · Last updated: Oct 7, 2026

2026 ACC HFpEF Expert Consensus Decision PathwayAmerican College of Cardiologyheart failure with preserved ejection fractionSGLT2 inhibitorsnonsteroidal MRA finerenoneGLP-1 and incretin therapiesARNIARB Cardiology / Anticoagulation

Background Information

New ACC guidelines streamline HFpEF management for clinicians.

Heart failure with preserved ejection fraction (HFpEF) is a complex condition requiring updated management strategies. The 2026 ACC guideline provides expert consensus on managing HFpEF based on current evidence and clinical practice. These guidelines aid clinicians in optimizing care for HFpEF patients, though the consensus is subject to change as new research emerges. The 2026 ACC guideline offers expert recommendations for managing heart failure with preserved ejection fraction.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kittleson MM, Panjrath GS, Bates K, Breathett KK, Dixon DL, Januzzi JL Jr, Mohammed SF

Citation: Kittleson MM, Panjrath GS, Bates K, et al. Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2026.06.018

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →